Mumbai Stocks to Buy in November 2026: 5 Names on the Watchlist
- November 4, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
L&T Rs 3,948. Sun Pharma Rs 1,770. Phoenix Rs 2,049. Ajanta Pharma Rs 3,320. Ipca Labs Rs 1,950. NSE closing prices, 3 Nov 2026.
Quick Answer
Five Mumbai stocks to buy on the November 2026 watchlist are Larsen and Toubro, Sun Pharmaceutical Industries, Phoenix Mills, Ajanta Pharma and Ipca Laboratories. All five grew revenue in their latest full year, and all five also grew net profit. Larsen and Toubro has the lowest P/E at 25.06, while Ajanta Pharma leads on return on equity at 23.33%. Check each valuation against your own risk appetite before acting.
The Mumbai stocks to buy in November 2026 start with five listed names: Larsen and Toubro, Sun Pharmaceutical Industries, Phoenix Mills, Ajanta Pharma and Ipca Laboratories. Mumbai stocks are listed companies headquartered in India’s financial capital, spanning engineering, pharma and real estate.
This article ranks none of them as a sure thing. It lays out the numbers each company has reported, how the shares are priced today and what an investor should check before adding any of these Mumbai stocks to buy to a portfolio. All prices are NSE closing prices of 3 November 2026, and financials come from company filings.
Click Here – Get Free Investment Predictions
Which Are the Best Mumbai Stocks to Buy in November 2026?
The best Mumbai stocks to buy in November 2026 for a watchlist are Larsen and Toubro, Sun Pharmaceutical Industries, Phoenix Mills, Ajanta Pharma and Ipca Laboratories. They were picked because each has complete reported financials, profit in the latest quarter and an NSE listing. The table puts their market data side by side.
| Company | CMP (Rs) | Market Cap | P/E | ROE | Dividend Yield |
|---|---|---|---|---|---|
| Larsen and Toubro | 3,948 | Rs 5,23,536 crore | 25.06 | 15.81% | 1.00% |
| Sun Pharmaceutical Industries | 1,770 | Rs 4,22,991 crore | 34.91 | 13.74% | 0.91% |
| Phoenix Mills | 2,049 | Rs 70,465 crore | 43.23 | 11.14% | 0.13% |
| Ajanta Pharma | 3,320 | Rs 43,234 crore | 38.10 | 23.33% | 0.81% |
| Ipca Laboratories | 1,950 | Rs 48,860 crore | 35.53 | 14.15% | 0.31% |
On valuation, Sun Pharmaceutical Industries, Ajanta Pharma and Ipca Laboratories sit close to it; Larsen and Toubro and Phoenix Mills carry a premium. Valuation is the first filter for any Mumbai stocks to buy list, and it is covered again in the risk section.
Why These Mumbai Stocks to Buy Are in Focus
Mumbai is home to the head offices of many of India’s largest listed companies. The list covers an engineering and construction conglomerate, India’s largest pharmaceutical company by market value, a retail-led mall developer, a branded generics company and a formulations and active ingredients maker. Investors comparing the best Mumbai stocks in India usually check earnings growth, margins and valuation.
Larsen and Toubro: The Infrastructure Conglomerate Among Mumbai Stocks to Buy
Larsen and Toubro is an engineering and construction conglomerate spanning infrastructure, defence, energy and IT services. At Rs 3,948, the stock has a market capitalisation of Rs 5,23,536 crore and trades at 25.06 times earnings, while the industry P/E is 21.53.
Reported numbers show FY26 revenue of Rs 2,91,635 crore, up 12.2% year on year, with net profit at Rs 19,159 crore, up 8.3%. The September 2026 quarter added revenue of Rs 81,056 crore (up 16.8%) and net profit of Rs 5,915 crore (up 26.2%).
Return on equity is 15.81%, debt-to-equity is 1.24, and the dividend yield is 1.00%. The company has no identified promoter, with foreign institutions holding 19.21% and domestic institutions 42.86% as of September 2026. A point to keep in view: debt is higher than most names on this list.
Sun Pharmaceutical Industries: The Pharma Heavyweight Among Mumbai Stocks to Buy
Sun Pharmaceutical Industries is India’s largest pharmaceutical company by market value, with a strong domestic franchise and a growing specialty portfolio in the US. Its market capitalisation is Rs 4,22,991 crore, the share price is Rs 1,770 and the P/E of 34.91 compares with an industry P/E of 37.65.
Over FY26, net profit rose 5.3% to Rs 11,565 crore on revenue of Rs 61,674 crore, which was up 12.7%. The latest quarter, the June 2026 quarter, brought revenue of Rs 16,024 crore, up 11.9% year on year, and net profit of Rs 2,911 crore, up 26.4%.
Return on equity is 13.74%, debt-to-equity is 0.06, and the dividend yield is 0.91%. Promoters hold 52.68%, foreign institutions 14.36% and domestic institutions 22.27% as of September 2026. Domestic institutional holding has risen from 20.23% to 22.27% over the last year.
Check Mumbai Stocks Live on the Univest Screener
Phoenix Mills: The Mall Owner Among Mumbai Stocks to Buy
Phoenix Mills is a retail-led developer that owns and operates large malls. The stock trades at Rs 2,049 with a market capitalisation of Rs 70,465 crore and a P/E of 43.23, against an industry P/E of 31.04.
FY26 revenue rose 15.9% to Rs 4,594 crore and net profit rose 19.6% to Rs 1,557 crore. In the June 2026 quarter, revenue grew 13.3% year on year to Rs 1,115 crore, while net profit grew 23.0% to Rs 394 crore.
Return on equity is 11.14%, debt-to-equity is 0.48, and the dividend yield is 0.13%. Promoters hold 47.24%, foreign institutions 31.62% and domestic institutions 17.31% as of September 2026. Domestic institutional holding has risen from 15.47% to 17.31% over the last year.
Ajanta Pharma: The Branded Generics Specialist Among Mumbai Stocks to Buy
Ajanta Pharma is a branded generics company with a strong presence in dermatology, ophthalmology and cardiology in India, Africa and Asia. At Rs 3,320, the stock has a market capitalisation of Rs 43,234 crore and trades at 38.10 times earnings, while the industry P/E is 37.65.
Reported numbers show FY26 revenue of Rs 5,625 crore, up 18.6% year on year, with net profit at Rs 1,056 crore, up 14.7%. The June 2026 quarter added revenue of Rs 1,697 crore (up 27.7%) and net profit of Rs 334 crore (up 30.9%).
Return on equity is 23.33%, debt-to-equity is 0.06, and the dividend yield is 0.81%. Promoters hold 63.47%, foreign institutions 7.63% and domestic institutions 21.94% as of September 2026. Domestic institutional holding has risen from 17.90% to 21.94% over the last year.
Ipca Laboratories: The Formulations and API Name Among Mumbai Stocks to Buy
Ipca Laboratories is a pharma company making formulations and active ingredients, known for anti-malarial and pain-management products. Its market capitalisation is Rs 48,860 crore, the share price is Rs 1,950 and the P/E of 35.53 compares with an industry P/E of 37.65.
Over FY26, net profit rose 51.3% to Rs 1,191 crore on revenue of Rs 9,821 crore, which was up 8.7%. The latest quarter, the June 2026 quarter, brought revenue of Rs 2,813 crore, up 20.2% year on year, and net profit of Rs 423 crore, up 80.4%.
Return on equity is 14.15%, debt-to-equity is 0.10, and the dividend yield is 0.31%. Promoters hold 44.72%, foreign institutions 11.53% and domestic institutions 36.59% as of September 2026. Foreign institutional holding has risen from 10.43% to 11.53% over the last year.
Download the Univest iOS App or Univest Android App to track these Mumbai stocks live and get daily stock recommendations.
Growth Snapshot: Latest Full Year and Latest Quarter
The table compares year-on-year growth in revenue and net profit for all five Mumbai stocks, using filed results.
| Company | Full-Year Revenue Growth | Full-Year Profit Growth | Latest Quarter | Quarter Revenue Growth | Quarter Profit Growth |
|---|---|---|---|---|---|
| Larsen and Toubro | 12.2% | 8.3% | Sep 2026 | 16.8% | 26.2% |
| Sun Pharmaceutical Industries | 12.7% | 5.3% | Jun 2026 | 11.9% | 26.4% |
| Phoenix Mills | 15.9% | 19.6% | Jun 2026 | 13.3% | 23.0% |
| Ajanta Pharma | 18.6% | 14.7% | Jun 2026 | 27.7% | 30.9% |
| Ipca Laboratories | 8.7% | 51.3% | Jun 2026 | 20.2% | 80.4% |
Factors That Move Mumbai Stocks to Buy
Four factors tend to drive Mumbai stocks, and each one is worth checking before a purchase.
- Order books: Engineering firms depend on project orders.
- Drug approvals: Pharma earnings follow product launches and approvals.
- Footfall: Malls depend on consumer spending.
- Valuation: Several names trade at premium multiples.
Risks to Keep in Mind Before Buying Mumbai Stocks
The first risk is that pharma earnings depend on product approvals, pricing and regulatory outcomes in export markets. The second is that engineering and mall businesses follow capex and consumer cycles. Valuations differ, so check each stock.
On the numbers, Phoenix Mills trades at the highest P/E on this list at 43.23, so its earnings need to keep growing to support the price. Mumbai stocks to buy can still fall when markets turn weak, and a staggered entry has historically suited investors better than a lump-sum purchase.
How to Choose Mumbai Stocks to Buy
- Check growth: Look for steady revenue and profit growth.
- Review margins: Stable margins show pricing power.
- Study sector exposure: Pharma, engineering and malls differ.
- Compare valuations: Premium multiples need steady results.
How to Invest in Mumbai Stocks
- Shortlist two or three companies from this list that match your risk appetite.
- Open the Univest Screener and compare P/E, ROE and debt for each stock.
- Check the latest quarterly results and shareholding pattern on NSE or BSE.
- Decide an amount you can hold for three to five years and split it into two or three purchases.
- Review the holding after every quarterly result instead of reacting to daily price moves.
Conclusion
Larsen and Toubro offers the lowest P/E on this list at 25.06, Ajanta Pharma has the highest return on equity at 23.33%, and Ipca Laboratories posted the fastest net profit growth in its latest full year at 51.3%. Among the best Mumbai stocks in India, these five give investors a spread of size, valuation and growth, so the right pick depends on risk appetite and holding period. Spread the entry, keep position sizes sensible and consult a SEBI-registered advisor before investing in any of these Mumbai stocks to buy.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Mumbai Stocks to Buy
Which are the best Mumbai stocks to buy in November 2026?
Ans. The five Mumbai stocks on the November 2026 watchlist are Larsen and Toubro, Sun Pharmaceutical Industries, Phoenix Mills, Ajanta Pharma and Ipca Laboratories. Larsen and Toubro has the lowest P/E at 25.06, Ajanta Pharma has the highest ROE at 23.33%, and Ipca Laboratories grew net profit 51.3% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.
Is Larsen and Toubro a good stock to buy from this Mumbai list?
Ans. Larsen and Toubro is the largest company on this list with a market capitalisation of Rs 5,23,536 crore and a P/E of 25.06 against an industry P/E of 21.53. Its FY26 revenue rose 12.2% and net profit rose 8.3%, with return on equity at 15.81%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.
Are these Mumbai stocks expensive right now?
Ans. Valuations vary across the group. Larsen and Toubro trades at a P/E of 25.06, Sun Pharmaceutical Industries trades at a P/E of 34.91, Phoenix Mills trades at a P/E of 43.23, Ajanta Pharma trades at a P/E of 38.10, Ipca Laboratories trades at a P/E of 35.53, against industry multiples ranging from 21.53 to 37.65. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.
Which of these Mumbai stocks pay a dividend?
Ans. Dividend yields on this list are Larsen and Toubro 1.00%, Sun Pharmaceutical Industries 0.91%, Phoenix Mills 0.13%, Ajanta Pharma 0.81%, Ipca Laboratories 0.31%. Yields are modest across the group, so most investors look at these stocks for growth in earnings rather than for income, and payouts can change with company profits.
Which stock on this list has the highest return on equity?
Ans. Ajanta Pharma has the highest ROE on this list at 23.33%, followed by Larsen and Toubro at 15.81% and Ipca Laboratories at 14.15%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.
What are the risks of investing in Mumbai stocks?
Ans. The main risks are regulatory outcomes in pharma, project and consumer cycles and premium valuations. On this list, Phoenix Mills trades at the highest P/E of 43.23, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.
How can I invest in Mumbai stocks in India?
Ans. You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.